Medtronic completed its acquisition of CathWorks for $585 million, including earn‑out potential, on April 20 2026. The deal brings the drug‑free, wire‑free FFRangio® System into Medtronic’s interventional cardiology lineup, enabling angiography‑derived fractional flow reserve across the entire coronary tree.
The FFRangio® System uses artificial intelligence and advanced computational science to analyze coronary angiograms and derive fractional flow reserve values without pressure wires or pharmacologic agents. FDA 510(k) clearance and CE marking support its clinical adoption, and a recent one‑year randomized trial at the 2026 American College of Cardiology conference demonstrated non‑inferiority to wire‑based physiology for major adverse cardiac events.
Medtronic’s management said the acquisition is a “tuck‑in” that strengthens its core business and accelerates growth in the high‑growth digital‑health segment of cardiovascular care. Senior vice president and president of the Coronary & Renal Denervation business, Jason Weidman, noted that the system “empowers physicians with data‑driven insights for the diagnosis and treatment of coronary artery disease.”
Financially, the transaction is expected to be immaterial to Medtronic’s fiscal 2027 GAAP and adjusted earnings per share, but it will become accretive thereafter. The $585 million purchase price, combined with earn‑out provisions, is projected to add incremental earnings once the new product line reaches full commercial scale, aligning with Medtronic’s strategy of targeted acquisitions to boost long‑term profitability.
The acquisition follows a strategic partnership and co‑promotion agreement that began in 2022, and it precedes Medtronic’s announced intent to acquire Scientia Vascular for $550 million. Together, these moves position Medtronic to capture a larger share of the evolving coronary physiology market and to integrate AI‑driven diagnostics into its broader interventional portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.